Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.
Also called NCT06690723
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 160 participants
- Sponsor
- University Malaysia Sarawak
- Registry
-
NCT06690723
-
- Other papers using this trial's data
- Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Malaysia
- Registry status
- Completed
Technical summary
Registry record NCT06690723. Randomized; single masking; primary purpose treatment. Start 2022-06-08 (actual); primary completion 2024-09-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea
- Acronym
- D3DOSA
- Condition
- Obstructive Sleep Apnea
- Intervention (Drug)
- Dapagliflozin (Forxiga)
- Intervention (Drug)
- Vitamin D3 ( Colecalciferol)
- Intervention (Drug)
- Vitamin D3 plus Dapagliflozin
- Intervention (Behavioral)
- Lifestyle modification
- Lead sponsor
- University Malaysia Sarawak
Record details
- Record id
cardio:ct-nct06690723- Content hash
2b4c40748e821a202c512f000fc2c84389c2e54ef88dad6fd60258e03bd4a7c9